Anteris Technologies' US IPO initiative

Anteris Technologies Ltd (ASX: AVR) has announced that its subsidiary, Anteris Technologies Global Corp. (ATGC), has commenced the roadshow for an Initial Public Offering (IPO) in the United States. The offering consists of 14,800,000 shares of common stock, with underwriters having the option to purchase an additional 2,220,000 shares. These shares will be listed on the Nasdaq Global Market under the ticker symbol 'AVR'.

Anteris Technologies' strategic IPO and future plans

Anteris Technologies Ltd is advancing its strategic goals with the US IPO launch through its subsidiary, Anteris Technologies Global Corp. The IPO aims to raise funds for the development of DurAVR®, a leading medical device designed to treat aortic stenosis. With innovative products featuring bioengineered tissue, Anteris is positioned to enhance its market presence. The company is focused on expanding its financial resources to support product development and a global study. The successful listing on Nasdaq will provide the necessary capital to push forward with these initiatives. This move is indicative of Anteris Technologies' ambition to strengthen its position in the medical device market and broaden its impact on structural heart disease treatment.

Insights from Anteris Technologies' strategic move

The funds raised from this IPO will primarily support the development of our DurAVR® transcatheter heart valve and a global study on its efficacy in treating severe aortic stenosis. Additionally, proceeds will be used for general corporate purposes and repayment of convertible notes.